{"entity":{"id":"nct04375683","kind":"trial","name":"Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL","aka":[],"tldr":"A phase 3 trial of Flumatinib in Leukaemia, run by Zhongda Hospital, with a status the registry has not verified recently.","summary":"Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL is a phase 3 interventional study registered as NCT04375683 by Zhongda Hospital, with 28 participants planned, started 2020-03-01 and due to reach its primary completion in 2022-12-30. Interventions recorded: Flumatinib. Conditions recorded: Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression.\n\nLinked to the drug Flumatinib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04375683","url":"https://clinicaltrials.gov/study/NCT04375683"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["flumatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04375683","phase":"3","setting":"A Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring","sponsor":"Zhongda Hospital","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04375683/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/"}]}}